Phathom Pharmaceuticals, Inc. EBT

EBT of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT growth rates and interactive chart. Earnings before tax (EBT) measures a company's financial performance. Its calculation is revenue minus expenses, excluding taxes. EBT is a line item on a company's income statement. It shows company earnings with the cost of goods sold (COGS), interest, depreciation, general and administrative expenses, and other operating expenses deducted from gross sales.

Highlights and Quick Summary

  • EBT for the quarter ending June 29, 2021 was $-36.6 Million (a 4.9% increase compared to previous quarter)
  • Year-over-year quarterly EBT increased by 7.17%
  • Annual EBT for 2020 was $-129 Million (a -49.41% decrease from previous year)
  • Annual EBT for 2019 was $-255 Million (a 19708.31% increase from previous year)
  • Twelve month EBT ending June 29, 2021 was $-159 Million (a 10.75% increase compared to previous quarter)
  • Twelve month trailing EBT decreased by -8.15% year-over-year
Trailing EBT for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-159 Million $-144 Million $-129 Million $-173 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT of Phathom Pharmaceuticals, Inc.

Most recent EBTof PHAT including historical data for past 10 years.

Interactive Chart of EBT of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EBT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-36.55 $-34.84
2020 $-53.72 $-34.11 $-21.1 $-20.14 $-129.07
2019 $-98.01 $-68.11 $-87.76 $-1.25 $-255.13
2018 $-0.29 $-1.29

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.